ReviewVaccines2013
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.
Review in Vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.
- Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39.Scientific reports · 2019Pooled it
- Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.Frontiers in immunology · 2025Trial
- Article
- Pre-Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae: Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis.Microbial biotechnology · 2026Article
- Bulky pcDNA plasmid encoding Leishmania- and Sandfly-derived antigens resulted in transient Th1 response post Leishmania major infection in BALB/c mice.Scientific reports · 2026Article
- DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations.International journal of molecular sciences · 2025Review
- Prospects and Challenges of Lung Cancer Vaccines.Vaccines · 2025Review
- Lipid nanoparticle-delivered IFNα2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis.Journal for immunotherapy of cancer · 2025Article
- Deciphering plasmid replication dynamics: a computational approach to predict ColE1-like plasmid copy number.Journal of the Royal Society, Interface · 2025Article
- Apyrase Protein (PsSP42) Expression in DNA Construct Transfected COS-7 Cells.Iranian biomedical journal · 2025Article
- Simple and robust in vivo engineering of plasmid DNA at any copy number in Escherichia coli.Communications biology · 2025Article
- Harnessing nc886 to overcome immune and apoptotic barriers in adenoviral gene therapy.Molecular therapy. Nucleic acids · 2025Article
- Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024Review
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security.Microorganisms · 2023Review
- Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform.International journal of molecular sciences · 2023Article
- Review
- Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.Molecular cancer · 2023Article
- Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).Archives of microbiology · 2023Review
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA vaccination is a disruptive technology that offers the promise of a new rapidly deployed vaccination platform to treat human and animal disease with gene-based materials. Innovations such as electroporation, needle free jet delivery and lipid-based carriers increase transgene expression and immunogenicity through more effective gene delivery. This review summarizes complementary vector design innovations that, when combined with leading delivery platforms, further enhance DNA vaccine performance. These next generation vectors also address potential safety issues such as antibiotic selection, and increase plasmid manufacturing quality and yield in exemplary fermentation production processes. Application of optimized constructs in combination with improved delivery platforms tangibly improves the prospect of successful application of DNA vaccination as prophylactic vaccines for diverse human infectious disease targets or as therapeutic vaccines for cancer and allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.